Home > Journals > Minerva Pneumologica > Past Issues > Minerva Pneumologica 2005 December;44(4) > Minerva Pneumologica 2005 December;44(4):141-78

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

REVIEWS   

Minerva Pneumologica 2005 December;44(4):141-78

Copyright © 2005 EDIZIONI MINERVA MEDICA

language: Italian

Topical mucolysis and antibiotic therapy in chronic diseases of airways with focus on cystic fibrosis

Melillo G., Passali D., Melillo E.


PDF


Qualitative and quantitative alterations of mucus can provoke and/or influence various diseases of the upper and lower airways. In order to prevent or limit such events, 2 strategies can be adopted: the mucolytic treatment and the antibiotic therapy. We refer to mucolysis which can be obtained by inhalatory administration of some tiolic mucolytics (i.e., having a free sulphidril group), such as N-acetylcysteine and sodium 2-mercaptoethane sulphidric, drugs endowed with an intense and rapid topical action. As typical disease, reference is made to cystic fibrosis, being probably the most typical situation of increased steady secretions and subsequent chronic airway inflammation causing marked symptoms of both lower and upper airways. Moreover, such disease requires chronic antibiotic therapy against Pseudomonas aeruginosa. Therapy is carried out by administering a tobramycin, adapted for inhalation, alternating 4 weeks of treatment and 4 treatment-free weeks. The observations regarding cystic fibrosis are obviously valid for other chronic airway diseases, such as bronchiectasis, purulent bronchitis, rhinosinusitis, otitis etc.

top of page